About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (19)
Anthony Letai, MD, PhD
Harvard Medical School
Zentalis Pharmaceuticals
team_member
Dave Johnson
Director
Zentalis Pharmaceuticals
team_member
Enoch Kariuki, PharmD
Director
Zentalis Pharmaceuticals
team_member
Funda Meric-Bernstam, MD
MD Anderson Cancer Center
Zentalis Pharmaceuticals
team_member
Haibo Wang
Chief Business Officer
Zentalis Pharmaceuticals
team_member
Henry Gu
Senior Vice President, Head of Intellectual Property
Zentalis Pharmaceuticals
executive
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
0
As Collaborator
2
Total Enrollment
78
By Phase
PHASE1/PHASE2: 1PHASE1: 1
By Status
RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06351332Collaborator
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
PHASE1/PHASE2Recruiting
78 participants
Started: May 1, 2024 · Completed: Sep 1, 2029
NCT05431582Collaborator
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
PHASE1Withdrawn
Started: Dec 14, 2022 · Completed: Dec 14, 2022
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...